Ignite Creation Date:
2024-05-05 @ 11:07 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00005571
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
2000-04-25
Brief Title:
Safety and Effectiveness of h5G11-mAb for Dermatomyositis
Sponsor:
National Institute of Arthritis and Musculoskeletal and Skin Diseases NIAMS
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
A Randomized Third-Party-Blind Placebo-Controlled Pilot Study of the Effect of h5G11-mAb on Dermatomyositis Patients
Status:
COMPLETED
Status Verified Date:
2001-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the safety and effectiveness of the experimental drug h5G11-mAb in treating patients with dermatomyositis This disease which causes skin rash muscle weakness and sometimes various other symptoms may be due to an immune system abnormality Drugs currently used to treat dermatomyositis such as prednisone and various anticancer drugs often have serious side effects and may not work in all patients h5G11-mAb is a genetically engineered antibody that blocks the activity of certain proteins involved in the immune reaction that produces inflammation
Patients age 18 years and older who have had dermatomyositis for at least 6 months and who have not improved with prednisone or other therapies or who cannot tolerate prednisone or other therapies may be eligible for this 12-week study Candidates will have a history and physical examination including blood and urine tests throat culture and muscle strength testing Participants will be randomly assigned to receive either h5G11-mAb or placebo an inactive substance The drug or placebo will be given intravenously through a thin tube inserted into a vein once a week for five doses and then every other week for two more doses
Participants will undergo the following additional tests at various intervals during the study as follows
1 Complete physical examination visit 9
2 Blood and urine tests various intervals
3 Muscle strength testing assessment of ability to perform daily tasks and completion of questionnaire regarding functional abilities visits 2 6 and 9
4 Ultrasound imaging of muscle during certain muscle exercises visits 2 6 and 9
5 Electrocardiogram EKG visits 2 and 9
6 Throat swab culture visit 6
7 Examination and photography of skin lesions visits 2 and 9
8 Skin biopsy - removal of small sample of skin tissue under local anesthetic visits 2 and 9
9 Magnetic resonance imaging MRI scan of muscles visits 2 and 9
10 Possible muscle biopsy - removal of small sample of muscle tissue under local anesthetic visits 2 and 9
Patients age 18 years and older who have had dermatomyositis for at least 6 months and who have not improved with prednisone or other therapies or who cannot tolerate prednisone or other therapies may be eligible for this 12-week study Candidates will have a history and physical examination including blood and urine tests throat culture and muscle strength testing Participants will be randomly assigned to receive either h5G11-mAb or placebo an inactive substance The drug or placebo will be given intravenously through a thin tube inserted into a vein once a week for five doses and then every other week for two more doses
Participants will undergo the following additional tests at various intervals during the study as follows
1 Complete physical examination visit 9
2 Blood and urine tests various intervals
3 Muscle strength testing assessment of ability to perform daily tasks and completion of questionnaire regarding functional abilities visits 2 6 and 9
4 Ultrasound imaging of muscle during certain muscle exercises visits 2 6 and 9
5 Electrocardiogram EKG visits 2 and 9
6 Throat swab culture visit 6
7 Examination and photography of skin lesions visits 2 and 9
8 Skin biopsy - removal of small sample of skin tissue under local anesthetic visits 2 and 9
9 Magnetic resonance imaging MRI scan of muscles visits 2 and 9
10 Possible muscle biopsy - removal of small sample of muscle tissue under local anesthetic visits 2 and 9
Detailed Description:
This is a randomized third-party placebo-controlled pilot study of h5G11-mAb an antibody directed at the complement component C5 administered to patients with dermatomyositis with persistent disease We are one of the four groups taking part in a multicenter trial under the sponsorship of Alexion Pharmaceuticals Inc
In dermatomytosis humorally-mediated damage to muscle and skin microvasculature appears very important The deposition of the membrane attack complex C5-9 on the capillaries has been shown to precede the destruction of muscle fibers and to be a specific finding in the skin lesion These observations along with the recent discovery of the effectiveness of intravenous gammaglobulin IVIG in dermatomyositis support the role of complement activation in the pathogenesis of dermatomyositis Among the activated components of the complement system the products that are generated after cleavage of C5 namely C5a and C5b-9 are potent inflammatory mediators with pleiotropic activities Inhibition of complement activation at C5 would prevent the formation of these pro-inflammatory molecules while allowing the generation of C3b which is critical for opsonization and immune complex clearance C5 inhibition therefore represents a potentially effective therapeutic modality for dermatomyositis
Anti-C5 monoclonal antibodies are designed to prevent the cleavage of C5 A murine monoclonal antibody to human C5 m5G11-mAb was humanized h5G11-mAb by grafting the antibodys antigen-binding CDR regions onto human antibody-derived framework and constant domains This antibody is being made available by Alexion Pharmaceuticals and will be used under their IND
There will be 15 patients entered with the goal of 12 evaluable patients distributed among two treatment groups Patients will be randomized at a 3 to 1 ratio between h5G11-mAb and placebo Following a screening period of no less than 7 days a 2 month double-blind randomized treatment period will commence Patients will receive an active h5G11-mAb 8mgkg bolus infusion every week X 5 then every 2 weeks X 2 or a placebo bolus infusion every week X 5 then every 2 weeks X 2 All patients will be receiving 7 infusions of h5G11-mAb or placebo
The objective is to determine the safety and tolerability of h5G11-mAb and to evaluate the pharmacokinetics and pharmacodynamics of this antibody as well as its efficacy in the target population Safety will be assessed via the collection of adverse events and the evaluation of pre- and post-treatment laboratory data Efficacy will be assessed by the change in the manual muscle testing score relative to placebo at 225 months one week following the end of the active treatment period primary efficacy value and the change in the muscle enzyme level MRI findings skin examination findings and biopsy and SF-36 secondary efficacy values
In dermatomytosis humorally-mediated damage to muscle and skin microvasculature appears very important The deposition of the membrane attack complex C5-9 on the capillaries has been shown to precede the destruction of muscle fibers and to be a specific finding in the skin lesion These observations along with the recent discovery of the effectiveness of intravenous gammaglobulin IVIG in dermatomyositis support the role of complement activation in the pathogenesis of dermatomyositis Among the activated components of the complement system the products that are generated after cleavage of C5 namely C5a and C5b-9 are potent inflammatory mediators with pleiotropic activities Inhibition of complement activation at C5 would prevent the formation of these pro-inflammatory molecules while allowing the generation of C3b which is critical for opsonization and immune complex clearance C5 inhibition therefore represents a potentially effective therapeutic modality for dermatomyositis
Anti-C5 monoclonal antibodies are designed to prevent the cleavage of C5 A murine monoclonal antibody to human C5 m5G11-mAb was humanized h5G11-mAb by grafting the antibodys antigen-binding CDR regions onto human antibody-derived framework and constant domains This antibody is being made available by Alexion Pharmaceuticals and will be used under their IND
There will be 15 patients entered with the goal of 12 evaluable patients distributed among two treatment groups Patients will be randomized at a 3 to 1 ratio between h5G11-mAb and placebo Following a screening period of no less than 7 days a 2 month double-blind randomized treatment period will commence Patients will receive an active h5G11-mAb 8mgkg bolus infusion every week X 5 then every 2 weeks X 2 or a placebo bolus infusion every week X 5 then every 2 weeks X 2 All patients will be receiving 7 infusions of h5G11-mAb or placebo
The objective is to determine the safety and tolerability of h5G11-mAb and to evaluate the pharmacokinetics and pharmacodynamics of this antibody as well as its efficacy in the target population Safety will be assessed via the collection of adverse events and the evaluation of pre- and post-treatment laboratory data Efficacy will be assessed by the change in the manual muscle testing score relative to placebo at 225 months one week following the end of the active treatment period primary efficacy value and the change in the muscle enzyme level MRI findings skin examination findings and biopsy and SF-36 secondary efficacy values
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 00-AR-0117 | None | None | None |